BioPharmSignal logoBioPharmSignal

Biotech News

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

Oric Pharmaceuticals, Inc. (ORIC)Oric Pharmaceuticals, Inc.Company update

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced that management will be

Related news

ORICOric Pharmaceuticals, Inc.2026-08-03 20:05 EST

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

ORICOric Pharmaceuticals, Inc.2026-07-14 20:05 EST

ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer

ZNTLZentalis2026-09-02 20:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

BMEABiomea Fusion2026-09-03 12:00 EST

Biomea Fusion to Participate in Upcoming Investor Conferences

KYMRKymera2026-09-02 20:01 EST

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

RLAYRelay Therapeutics2026-09-01 20:46 EST

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September

NRIXNurix Therapeutics2026-09-01 12:00 EST

Nurix Therapeutics to Participate in Upcoming September Investor Conferences

CHRSCoherus BioSciences, Inc.2026-08-31 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

MMSIMerit Medical2026-09-04 13:25 EST

Merit Medical to Participate in Upcoming Investors Conferences in September

KURAKura Oncology2026-09-01 11:15 EST

Kura Oncology to Participate in Three Investor Conferences in September

View all latest news

Oric Pharmaceuticals, Inc.

Oncology Resistance Biology ORIC Pharmaceuticals develops therapies intended to overcome mechanisms of treatment resistance in cancer. Its programs target epigenetic and signaling pathways that allow tumors to adapt to standard treatments. Rinzimetostat Rinzimetostat is an allosteric EED inhibitor that suppresses PRC2 activity. It is...

Recent company news

ORICOric Pharmaceuticals, Inc.2026-09-04 20:30 EST

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORICOric Pharmaceuticals, Inc.2026-09-02 20:05 EST

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences

ORICOric Pharmaceuticals, Inc.2026-08-07 20:30 EST

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORICOric Pharmaceuticals, Inc.2026-08-03 20:05 EST

ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates

ORICOric Pharmaceuticals, Inc.2026-07-20 12:30 EST

ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

Stock data

Close
12.88 USD
Market cap
788.8M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States